# A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)

> **NCT01314664** · — · TERMINATED · sponsor: **Endo Pharmaceuticals** · enrollment: 15 (actual)

## Conditions studied

- Bladder Cancer
- CIS

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01314664
- **Lead sponsor:** Endo Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2011-05
- **Primary completion:** 2012-01
- **Final completion:** 2012-01
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Business decision, not safety related
- **Last updated:** 2015-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01314664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01314664, "A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects With Non-muscle Invasive Bladder Cancer (NMIBC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01314664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*